Finally, this NGS approach revealed gains of different regions including MUTYH, CDK4, KRAS, POLE, ERBB2, TP53, POLD1, and STK11 in both NEC and endometrioid tumors. This evidence concerns the gene ERBB2 and neuroendocrine carcinoma.